Hunter Diamond

Ahu Demir

Aydin Huseynov

Mike King

- Salarius Pharmaceuticals, Inc. entered into a **Fifth Amendment to its Agreement and Plan of Merger** on **September 17, 2025**, with Decoy Therapeutics Inc. and its subsidiaries.  **[1615219_0001615219-25-000135_projectsierra-fifthamendme.htm:0]** **[1615219_0001615219-25-000135_flks-20250917.htm:1]** 
- The amendment modifies the conversion terms for Series A and Series B Non-Voting Convertible Preferred Stock, establishing an **Initial Issuance Price of $10.50 per share** as the baseline for conversion ratio adjustments in dilutive subsequent financings.  **[1615219_0001615219-25-000135_flks-20250917.htm:1]** 
- A **floor price of $3.75 per share** has been set for the price protection calculation triggered by a Subsequent Financing.  **[1615219_0001615219-25-000135_flks-20250917.htm:1]** 
- The **redemption price per share of Series B Preferred Stock** was changed to the Initial Issuance Price multiplied by 1,000.  **[1615219_0001615219-25-000135_flks-20250917.htm:1]** **[1615219_0001615219-25-000135_certificateofdesignations-.htm:15]**

Salarius Pharmaceuticals (SLRX)